CVS Health to Split Drugstore and Insurance Units in Major Restructuring

CVS Health is preparing to dismantle its $117 billion healthcare empire, planning to separate its namesake retail pharmacy chain from its insurance and pharmacy benefit operations. The proposed split, expected to be completed in the first half of 2028, marks a dramatic reversal for the largest healthcare conglomerate in the United States.[1][2]

Under the plan, the Rhode Island-based company will divide into two publicly traded entities. One company will retain the CVS Health name and house the Aetna health insurance business alongside the Caremark pharmacy benefit manager.[2][4]

The second entity, to be named CVS Pharmacy, will take control of the company's consumer-facing operations. This includes roughly 9,000 retail drugstores, the mail-order pharmacy business, and the nearly 1,000 MinuteClinic retail health locations staffed by nurse practitioners.[2][4]

The retail division has long served as the public face of the company, processing hundreds of millions of prescriptions annually. By spinning off the drugstores, CVS Pharmacy will operate as a pure-play retailer, focusing entirely on prescription fulfillment, over-the-counter health products, and basic clinical services.[2][4]

Current Chief Executive Officer David Joyner, who took the helm in October 2024, is expected to stay on and lead the insurer-side company. Joyner has spent the past two years working to stabilize the broader business after the Aetna unit stumbled amid rising medical costs.[2][3]

"We believe based off of where we are and how we're performing, the businesses are best served by splitting," Joyner reportedly told colleagues. The internal remarks, cited in coverage of the deliberations, highlight a stark departure from the company's previous messaging.[3]

The restructuring proposal arrives just as CVS prepares to report its third-quarter earnings on Wednesday. The company's retail pharmacy operation is projected to generate approximately $138 billion in revenue in 2024, representing about a third of the conglomerate's total sales.[1][2]

Unwinding the Aetna acquisition

The separation effectively undoes the central premise of CVS's $78 billion acquisition of Aetna in 2018. At the time, executives argued that combining a massive drugstore chain with the nation's third-largest health insurer would bend the healthcare cost curve in ways no rival could match.[1][4]

The 2018 Aetna deal was the culmination of a long-term strategy to transform CVS from a traditional retailer into a comprehensive healthcare provider. Former Chief Executive Larry Merlo championed the merger, arguing that combining medical benefits with local pharmacy access would create a new front door for American healthcare.[1][2]

For nearly a decade, CVS championed a vertically integrated model. The strategy relied on steering Aetna's 26 million health plan members to CVS pharmacies and MinuteClinic sites, theoretically converting what would be costs in the insurance unit into revenue for the retail division.[2][4]

The company doubled down on this approach in recent years by acquiring primary care and home health providers. Those assets, including the senior care center operator Oak Street Health and the home health firm Signify Health, will remain attached to the Aetna and Caremark business after the split.[2][4]

However, the integrated model has faced severe financial headwinds. Health insurers across the industry have struggled with surging medical costs as patients increased their use of healthcare services following the COVID-19 pandemic, squeezing Aetna's profit margins.[1][3]

Aetna has also grappled with challenges in its Medicare Advantage portfolio. The insurer exited the Affordable Care Act individual exchanges this year and has been forced to cut back on benefits and offerings in its Medicare plans for older adults and people with disabilities.[1][3]

Regulatory and political scrutiny

The decision to break up the company coincides with intense scrutiny from federal regulators and lawmakers regarding healthcare consolidation. Pharmacy benefit managers like Caremark, which act as middlemen negotiating drug prices between manufacturers and insurers, have become a primary target in Washington.[3][4]

Critics argue that joint ownership of a pharmacy benefit manager, an insurer, and a retail pharmacy creates inherent conflicts of interest that drive up prescription costs. Earlier this year, U.S. Senators Elizabeth Warren and Josh Hawley introduced the "Break Up Big Medicine Act" to address industry consolidation.[4]

The legislative pressure is not limited to the federal level. Several states, including Arkansas and Tennessee, have recently passed laws designed to prohibit pharmacy benefit managers from owning their own retail pharmacies, directly threatening the core CVS business model.[4]

The Federal Trade Commission has also been investigating the business practices of the largest pharmacy benefit managers. Regulators have raised concerns that vertically integrated healthcare giants use their market power to steer patients to their own affiliated pharmacies, disadvantaging independent drugstores.[3][4]

Caremark is already feeling the commercial impact of this shifting landscape. CVS executives disclosed in August that the pharmacy benefit manager expects to lose several large clients in 2027 after taking a more cautious approach to pricing and contract negotiations.[3]

Market reaction and next steps

Analysts suggest that separating the businesses could allow investors to value each entity more clearly. Currently, CVS's stock reflects a blended narrative that mixes the economics of health insurance with the distinct risks of retail pharmacy foot traffic and contract retention.[1][3]

Shares of CVS moved higher in after-hours trading following the initial reports of the planned split, rising as much as 3.7 percent. The stock has rebounded slightly since Joyner took over, helping lift the company's market capitalization back to its current $117 billion valuation.[1][3]

AI

While a breakup might relieve regulatory pressure, it carries significant financial risks. Unwinding the conglomerate will incur substantial corporate standup costs, and the two new companies will lose the internal financial synergies that came from operating under a single corporate umbrella.[1][3]

For employers and patients, the split raises immediate questions about network access. If CVS pharmacies become an independent company, their contracts with Caremark and Aetna will have to be negotiated at arm's length, potentially altering preferred-pharmacy arrangements and mail-order steering.[2][4]

It remains unclear how the clinical integration between Aetna and the retail clinics will survive the separation. Aetna members currently enjoy seamless access to MinuteClinic services, a feature that has been a major selling point for employer group renewals.[2][4]

The standalone CVS Pharmacy business will also have to navigate a challenging retail environment. Despite closing hundreds of underperforming stores in recent years, the chain still faces fierce competition from online retailers and shifting consumer shopping habits that threaten front-of-store sales.[1][2]

Executing a corporate divorce of this magnitude will require significant time and resources. The projected timeline stretches into the first half of 2028, giving the company a multi-year runway to untangle its shared technology systems, executive compensation, and real estate footprint.[1][2]

AI

While the framework for the split is in place, sources caution that the exact structure and timing remain in flux. The board of directors could still alter the plan based on market conditions, regulatory feedback, or the performance of the underlying businesses over the next year.[1][3]

As CVS prepares to brief investors on Wednesday morning, the broader healthcare industry will be watching closely. The dismantling of the sector's most ambitious vertical integration experiment could prompt other healthcare conglomerates to reevaluate their own sprawling corporate structures.[1][4]